Moderna’s stock has been in the middle of its longest downturn in more than two years, having lost 50% of its value since August, when it hit a record high.
The downturn in a few months has eliminated $ 98 billion in company capitalization. Although the Omicron mutation of the coronavirus is sweeping the globe, Moderna’s stock is under pressure mainly due to the appearance of Pfizer and Merck pills, which have recently received approval from the US Food and Drug Administration (FDA).
Today, the stock closed with a loss of 2.2%, at $ 241.44. In the last six days, it has lost 18% of its value, with Moderna losing $ 22 billion in capitalization.
From the beginning of 2021, however, the share continues to record gains of 131%. Moderna, which joined the S&P 500 in July, is among the winners of the year in the index, behind only Tesla, which has jumped in the last two years.
Pfizer shares also fell today, having recently reached a record high on December 16th. Germany’s BioNTech, which developed Moderna’s competitor to the coronavirus mRNA (produced and distributed by Pfizer), is also in the midst of its biggest decline since September 2020.
.
I am Sophia william, author of World Stock Market. I have a degree in journalism from the University of Missouri and I have worked as a reporter for several news websites. I have a passion for writing and informing people about the latest news and events happening in the world. I strive to be accurate and unbiased in my reporting, and I hope to provide readers with valuable information that they can use to make informed decisions.
